Literature DB >> 7687062

Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.

U Gether1, Y Yokota, X Emonds-Alt, J C Brelière, J A Lowe, R M Snider, S Nakanishi, T W Schwartz.   

Abstract

The molecular mechanism of action for two chemically distinct and highly selective, nonpeptide antagonists, CP-96,345 and SR-48,968, was studied by development of a series of chimeric constructs between their respective target receptors, the NK1 (substance P) and NK2 (neurokinin A) receptors. The binding affinities of the natural peptide ligands, substance P and neurokinin A, were not affected by exchanging almost the entire C-terminal half of the NK1 receptor with the corresponding segment of the NK2 receptor. In contrast, it was found that transfer from the NK2 to the NK1 receptor of a segment corresponding to transmembrane segment VI, the amino-terminal half of transmembrane segment VII, and the connecting extracellular loop 3 completely switched the susceptibility for the nonpeptide antagonists. This chimeric exchange, corresponding to 17 nonconserved residues, conveyed full susceptibility for the NK2-specific compound SR-48,968 to the previously unresponsive NK1 receptor--i.e., the Ki value for inhibition of binding of 125I-labeled substance P decreased from > 10,000 to 0.97 nM. At the same time the affinity for the NK1-selective compound CP-96,345 decreased > 30-fold. The actual binding site for SR-48,968 was localized to this region of the NK2 receptor by use of [3H]SR-48,968, which did not bind to the NK1 receptor but bound with similar high affinities to the wild-type NK2 receptor and to the chimeric NK1 receptor with the NK2 receptor segment incorporated around transmembrane segments VI and VII, Kd = 1.5 nM and 1.0 nM, respectively. Our data indicate that two chemically very different nonpeptide antagonists, CP-96,345 and SR-48,968, act through epitopes located around transmembrane segment VI on their respective target receptors and that at least the nonconserved residues in these epitopes are not important for the binding of the natural peptide ligands, substance P and neurokinin A.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687062      PMCID: PMC46894          DOI: 10.1073/pnas.90.13.6194

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Demonstration of two distinct tachykinin receptors in rat brain cortex.

Authors:  M A Cascieri; G G Chicchi; T Liang
Journal:  J Biol Chem       Date:  1985-02-10       Impact factor: 5.157

2.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

3.  An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2.

Authors:  B Seed
Journal:  Nature       Date:  1987 Oct 29-Nov 4       Impact factor: 49.962

Review 4.  Substance P.

Authors:  B Pernow
Journal:  Pharmacol Rev       Date:  1983-06       Impact factor: 25.468

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Chimeric NK1 (substance P)/NK3 (neurokinin B) receptors. Identification of domains determining the binding specificity of tachykinin agonists.

Authors:  U Gether; T E Johansen; T W Schwartz
Journal:  J Biol Chem       Date:  1993-04-15       Impact factor: 5.157

7.  Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345.

Authors:  T M Fong; M A Cascieri; H Yu; A Bansal; C Swain; C D Strader
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

Review 8.  Chimeric alpha 2-,beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity.

Authors:  B K Kobilka; T S Kobilka; K Daniel; J W Regan; M G Caron; R J Lefkowitz
Journal:  Science       Date:  1988-06-03       Impact factor: 47.728

9.  Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function.

Authors:  C D Strader; I S Sigal; M R Candelore; E Rands; W S Hill; R A Dixon
Journal:  J Biol Chem       Date:  1988-07-25       Impact factor: 5.157

10.  Structural features required for ligand binding to the beta-adrenergic receptor.

Authors:  R A Dixon; I S Sigal; M R Candelore; R B Register; W Scattergood; E Rands; C D Strader
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  5 in total

1.  The conformation of substance P in lipid environments.

Authors:  D A Keire; T G Fletcher
Journal:  Biophys J       Date:  1996-04       Impact factor: 4.033

2.  Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat.

Authors:  P Picard; L Chrétien; R Couture
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

3.  Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors.

Authors:  H T Schambye; S A Hjorth; D J Bergsma; G Sathe; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

4.  Biased Gs versus Gq proteins and β-arrestin signaling in the NK1 receptor determined by interactions in the water hydrogen bond network.

Authors:  Louise Valentin-Hansen; Thomas M Frimurer; Jacek Mokrosinski; Nicholas D Holliday; Thue W Schwartz
Journal:  J Biol Chem       Date:  2015-08-12       Impact factor: 5.157

5.  Comparison of tachykinin NK1 and NK2 receptors in the circular muscle of the guinea-pig ileum and proximal colon.

Authors:  C A Maggi; R Patacchini; S Meini; L Quartara; A Sisto; E Potier; S Giuliani; A Giachetti
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.